HUE032486T2 - Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására - Google Patents
Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására Download PDFInfo
- Publication number
- HUE032486T2 HUE032486T2 HUE10838355A HUE10838355A HUE032486T2 HU E032486 T2 HUE032486 T2 HU E032486T2 HU E10838355 A HUE10838355 A HU E10838355A HU E10838355 A HUE10838355 A HU E10838355A HU E032486 T2 HUE032486 T2 HU E032486T2
- Authority
- HU
- Hungary
- Prior art keywords
- hmb
- acid
- muscle
- hydroxy
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
- láVÍTOlT ELJÂE.4S BÈ1^\4I1ÛRC>KI»BÉ1'A-MET1.L4RITIRÂT (Il MB) ADÂGOI, ÂSÂMA igéuypontnk L Kévotmeoy, ronds tartalmaz b&.v-btdto\t'hotn-moiU-vaj\3v.tt tHMB-t,s szabad sav B-IMB-sav) formájában, alkalmazás céljaitól a BMB hatékonyságának a jav kására a? adagolás során, összehasonlítva egy kalemmfo-HMB-kész ítmény agy ugyanolyan dózisának az adagolásával, i/smskároxodös xsőkkentésére stressznek kitett izomban, tzomkátosodás foks......kH i' l i m\ ást., k K. ·, Ή' ' <. av χ < ns s t ο η >,* \ >m,e unsthbasa s y'N K,s~xégcet suj\ χοΐ,ηοχ \o " xB' m. I* Készfonény alkalmazás céljából az h igénypont szerint ahol a HMB-sav egy gélfom vagy egy folyadékként van formai ázva.
- 3, Készítmény a/ 1, igénypont vagy a 2. îgény^>ft|-;poiihi|i.: !$*«% klkklitniöy formájában all rendelkezésre. 4 Készítmény az 1--461 .Víg igénypontok bármelyike szerint, amely egf Mnblíngváhs készítmény fornn) tóban all rendelkezésre, dk Készítmény alknlnwis céljából az előzd igénypontok bármelyike szerint, ahol a HMBfoáv a következő mennyiségben v an jelen: Cls5 grammtól 30 grammig 4 Készítmén> alkalmazás céljából hz ó igénypont szerint. ahol a líMB-mv egy alkalommal X an aüugoh n egy huszonnégy órás időtartam a lan, % Készítmény az l.-tól 4-ig igénypontok bármelyike szerint, «hol a IIMB-sav a koyéílégi mennyiségben van adagolva: 0,01 grammtól 42 grammig 11MB-sav per kilogramm teslfomeg per huszonnégy éra. 8 V í tCíoo o eh, «> müiiídt' ,cnen> pttbogen ' --- na,, V jav tu »ám, protein-kímélés tangóink „protein sparing") javítására. zsírmentes «sovány) fostrrimeg javítására, izom-í miken* ponto a, í *. n tel rstt χ,ην as« asarn t. \ x \ hpsO p utn iah lavawa vagy egy személy érzelmi álUtjxnanak Újítására, ahoi az magában foglalja bcmehitlrozl-béta^metil-vajsav folMB} adagolásál szabad sav (HMB-sav) formájában. 4 P'hárás a 8. igénypont s/c.mt, ohd a HMB-sav egy gélként vagy egy tol védőkként van fonntsiázva. '14 kijárás a 8. igénypont vagy a 9, igénypont szerinti ahol a HMB-sav egy orális készítmény v-agy xz.ifolmyvxdiss készítmény for májában áll rendelkezésre, H, Hljamo a χ >fo ló - te no a vss-x K. nebske er sru ától . Ih\!B ae a kínét ke,<> mennyiségben van jelen: 0,5 grammtól 30 grammig.
- 12, Eljárás a 11. igénypont szerint, ahol a IlMB-sos egy a Utalom tv t ai von adagok a egy huszonnégy órás időtartam alatt. .14 Eljárás a 8,-tói 12.-ig igénypontok bármelyike szeréit, öböl ahol a HMB-'-av a következe nvrtfx.segoen nfo-goo· , 401 ja a," ótól 4 man-tmg 11Mb \a- r-! k, vgmtnm testtömeg per huszonnégy óra. lé ktX'U'xM ,um V t, on « hm fotó v bzta , Htl vatsavo ,)IVB u xts íHMIKsav) tor májában egy gél formuládéként
- 15, Készítmény, amely tartalmaz, héia-hidrími-bétasooiu-vagsava! tMMB-u -znbad sav iUMB-sas'í fo< o^aban 'gv fdvadék tótmttlameké'« lő, Készítmény az 14. vagy 15. Igénypont szerint, amely egy orális készítmény vagy egy msbiingvális készítmény formájában áll rendelkezésre. i
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28785709P | 2009-12-18 | 2009-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032486T2 true HUE032486T2 (hu) | 2018-05-02 |
Family
ID=44167737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10838355A HUE032486T2 (hu) | 2009-12-18 | 2010-12-20 | Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására |
Country Status (11)
Country | Link |
---|---|
US (1) | US20120053240A1 (hu) |
EP (1) | EP2512236B1 (hu) |
JP (2) | JP6077857B2 (hu) |
CN (1) | CN102762097B (hu) |
CA (1) | CA2784836C (hu) |
DK (1) | DK2512236T3 (hu) |
ES (1) | ES2608483T3 (hu) |
HU (1) | HUE032486T2 (hu) |
PL (1) | PL2512236T3 (hu) |
PT (1) | PT2512236T (hu) |
WO (1) | WO2011075741A1 (hu) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108261547A (zh) * | 2011-07-15 | 2018-07-10 | 纽斯尔特科学公司 | 用于调节代谢途径的组合物和方法 |
EP3733171B1 (en) * | 2012-09-10 | 2023-10-25 | Metabolic Technologies, LLC | Compositions comprising hmb and atp as well as their use |
US20140272000A1 (en) * | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
US9713598B2 (en) | 2013-03-14 | 2017-07-25 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
EP2993994A4 (en) * | 2013-03-14 | 2016-11-23 | Metabolic Technologies Inc | LIQUIDS AND FOODS WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) IN A FREE ACID FORM |
WO2015137965A1 (en) * | 2014-03-14 | 2015-09-17 | Metabolic Technologies, Inc. | Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (hmb) in free acid form |
JP2016512686A (ja) * | 2013-03-15 | 2016-05-09 | アボット・ラボラトリーズAbbott Laboratories | カルシウムβ−ヒドロキシ−β−メチルブチレート、カゼインホスホペプチドおよびタンパク質を含む栄養組成物 |
US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
US10188611B2 (en) * | 2013-12-18 | 2019-01-29 | Capsugel Belguim NV | Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid |
WO2015105981A2 (en) * | 2014-01-09 | 2015-07-16 | Abbott Laboratories | Conditional essentiality of hmb |
US10293337B2 (en) | 2014-01-28 | 2019-05-21 | The Methodist Hospital | Single-cell pipette assembly comprising single-cell pipette handle and single-cell pipette tip |
JP6309287B2 (ja) * | 2014-01-29 | 2018-04-11 | 協和発酵バイオ株式会社 | 3−ヒドロキシ−3−メチル酪酸カルシウム含有飲料 |
US20160184248A1 (en) * | 2014-12-15 | 2016-06-30 | University Of Central Florida Research Foundation Inc. | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response |
WO2016196637A1 (en) * | 2015-06-01 | 2016-12-08 | Metabolic Technologies, Inc. | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass |
JP7114458B2 (ja) * | 2015-09-16 | 2022-08-08 | メタボリック・テクノロジーズ,インコーポレーテッド | 軟組織外傷からの回復を増強するためのβ-ヒドロキシ-β-メチルブチレート(HMB)の組成物および使用方法 |
AU2016353003B2 (en) | 2015-11-10 | 2021-06-10 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) as an animal feed additive |
EP3402476A4 (en) * | 2016-01-13 | 2019-09-18 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS FOR USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR JOINT STABILITY |
MX2018008903A (es) | 2016-01-21 | 2019-02-21 | Metabolic Tech Inc | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
WO2017205673A1 (en) * | 2016-05-25 | 2017-11-30 | TSI Group Ltd. | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
US10588877B2 (en) | 2016-07-21 | 2020-03-17 | Savind, Inc. | Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same |
EP3528801B1 (en) | 2016-10-21 | 2024-07-17 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics |
US20200276143A1 (en) * | 2016-10-21 | 2020-09-03 | Metabolic Technologies, Inc. | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics |
JP7022420B2 (ja) * | 2017-06-30 | 2022-02-18 | 株式会社東洋新薬 | 経口組成物 |
US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
KR20200131810A (ko) * | 2018-01-05 | 2020-11-24 | 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 | 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법 |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US10888576B2 (en) | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US20220062216A1 (en) * | 2020-08-26 | 2022-03-03 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
US5348979A (en) * | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
US6893627B2 (en) * | 2001-08-31 | 2005-05-17 | Rutgers, The State University Of New Jersey | Method for treating type 2 diabetes with an extract of Artemisia |
DE10215007A1 (de) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen |
US20040220266A1 (en) * | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
WO2005096846A1 (en) * | 2004-03-11 | 2005-10-20 | Wiley Organics, Inc. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
ES2689700T3 (es) * | 2008-12-09 | 2018-11-15 | Metabolic Technologies, Inc. | Intervención nutricional para mejorar la función y resistencia muscular |
JP2009155336A (ja) * | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
-
2010
- 2010-12-20 ES ES10838355.5T patent/ES2608483T3/es active Active
- 2010-12-20 PT PT108383555T patent/PT2512236T/pt unknown
- 2010-12-20 US US12/973,803 patent/US20120053240A1/en not_active Abandoned
- 2010-12-20 CN CN201080064031.3A patent/CN102762097B/zh active Active
- 2010-12-20 CA CA2784836A patent/CA2784836C/en active Active
- 2010-12-20 EP EP10838355.5A patent/EP2512236B1/en active Active
- 2010-12-20 PL PL10838355T patent/PL2512236T3/pl unknown
- 2010-12-20 JP JP2012544948A patent/JP6077857B2/ja active Active
- 2010-12-20 WO PCT/US2010/061367 patent/WO2011075741A1/en active Application Filing
- 2010-12-20 DK DK10838355.5T patent/DK2512236T3/en active
- 2010-12-20 HU HUE10838355A patent/HUE032486T2/hu unknown
-
2015
- 2015-09-25 JP JP2015188107A patent/JP2016026181A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102762097A (zh) | 2012-10-31 |
PT2512236T (pt) | 2016-12-29 |
JP6077857B2 (ja) | 2017-02-08 |
CN102762097B (zh) | 2015-06-17 |
CA2784836C (en) | 2019-08-20 |
WO2011075741A1 (en) | 2011-06-23 |
JP2013515009A (ja) | 2013-05-02 |
EP2512236A1 (en) | 2012-10-24 |
JP2016026181A (ja) | 2016-02-12 |
EP2512236B1 (en) | 2016-10-19 |
EP2512236A4 (en) | 2013-06-19 |
ES2608483T3 (es) | 2017-04-11 |
CA2784836A1 (en) | 2011-06-23 |
DK2512236T3 (en) | 2017-01-16 |
PL2512236T3 (pl) | 2017-06-30 |
US20120053240A1 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784836C (en) | Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb) | |
US20200268701A1 (en) | Compositions and methods for producing elevated and sustained ketosis | |
JP5690261B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 | |
JP2008534599A (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
EP1087779A2 (en) | Compositions for increasing energy in vivo | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
US20210113501A1 (en) | Method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
KR20230124538A (ko) | 운동 없이 근육량, 근력 및 근육 기능을 개선하기 위한 β-하이드록시-β-메틸부티레이트(HMB)의 조성물 및 사용 방법 | |
MXPA00011686A (es) | Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso |